This site is intended for health professionals only
Saturday 15 December 2018
Share |

Topic: crohn's disease

October 25, 2018
New study data also confirm efficacy for Stelara (ustekinumab) in Crohn's disease patients who are naïve and refractory/intolerant to tumour necrosis factor antagonist treatment

Janssen has announced new three-year data from the IM-UNITI study, which demonstrates the continued efficacy of ustekinumab in improving clinical remission rates and shows ustekinumab to be generally well-tolerated in patients with Crohn’s disease.1

The data from the IM-UNITI trial, which will continue for a further two years, were presented today at the 26th United European Gastroenterology Week (UEGW) congress in Austria, Vienna.

February 19, 2018
PANTS study shows that CT-P13 is an efficacious therapy option when investigating personalised approaches to anti-TNF therapy

Twelve-month data from the Personalised Anti-TNF therapy in Crohn’s disease Study (PANTS) was presented at the 13th Congress of the European Crohn’s and Colitis Organisation (ECCO).

The results indicate that the clinical effectiveness, safety and immunogenicity of Pfizer and Celltrion Healthcare’s CT-P13 (biosimilar infliximab) in patients with Crohn’s disease (CD) is comparable to those treated with reference infliximab as well as those treated with adalimumab.1

November 2, 2017
CT-P13 shown to be comparable in efficacy and safety to reference infliximab in switched inflammatory bowel disease patients

Celltrion Healthcare and Pfizer have jointly announced data from the Phase III, randomised controlled, switching trial comparing CT-P13 and reference infliximab.

The data showed comparable efficacy and safety between all treatment groups (maintained and switched) in patients with moderate to severe Crohn’s disease (CD) up to one year.1

November 2, 2017
Late-breaking data demonstrate rapid improvement in patient-reported symptoms in patients intolerant or refractory to anti-TNF treatment

Janssen has presented new late-breaking data from UNITI-1 assessing Crohn's disease symptom improvement in patients during the first 2 weeks after an intravenous (IV) infusion dose of Stelara®(ustekinumab).1

The data presented at the 25th United European Gastroenterology Week (UEGW 2017) showed that patient-reported symptom improvement began as early as day 1 post ustekinumab IV infusion and was observed consistently at day 8 and beyond when compared with placebo.1

September 16, 2016
If approved, Stelara® will be the first interleukin (IL)-12/23 inhibitor licensed for Crohn’s disease

January 11, 2016
In a study of 397 patients with ulcerative colitis and Crohn’s disease, 93 patients (23%) were switched to a biosimilar infliximab from the reference infliximab, representing the largest group of switch patients studied to date in inflammatory bowel diseases
  • In a study of 397 patients with ulcerative colitis and Crohn’s disease, 93 patients (23%) were switched to a biosimilar infliximab from the reference infliximab, representing the largest group of switch patients studied to date in inflammatory bowel diseases (IBD)1